Cumulative incidence of MMR. * indicates patients with atypical transcripts at baseline or missing molecular assessments by the indicated time point were considered nonresponders. Absolute difference between rates of MMR in the nilotinib arm vs the imatinib arm: by 12 months, 25.1% (95% CI, 13.6%-36.6%); by 24 months, 15.3% (95% CI, 3.7%-26.9%). †, P value is nominal. ‡, Response rates consider each month to consist of one 28-day cycle.